1
|
Westrich JA, McNulty EE, Carpenter M, Burton M, Reed K, Nalls A, Sandoval A, Mayo C, Mathiason CK. Monitoring longitudinal immunological responses to bluetongue virus 17 in experimentally infected sheep. Virus Res 2023; 338:199246. [PMID: 37858729 PMCID: PMC10594635 DOI: 10.1016/j.virusres.2023.199246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 10/14/2023] [Accepted: 10/16/2023] [Indexed: 10/21/2023]
Abstract
Bluetongue virus (BTV) is an economically important pathogen of ruminant species with worldwide prevalence. While many BTV infections are asymptomatic, animals with symptomatic presentation deteriorate quickly with the sickest succumbing to disease within one week. Animals that survive the infection often require months to recover. The immune response to BTV infection is thought to play a central role in controlling the disease. Key to understanding BTV disease is profiling vertebrate host immunological cellular and cytokine responses. Studies to characterize immune responses in ruminants have been limited by a lack of species-specific reagents and assay technology. Here we assess the longitudinal immunological response to experimental BTV-17-California (CA) infection in sheep using the most up to date assays. We infected a cohort of sheep with BTV-17-CA and longitudinally monitored each animal for clinical disease, viremia and specific immunological parameters (B cells, T cells, monocytes) by RT-qPCR, traditional flow cytometry and/or fluorescent based antibody arrays. BTV-inoculated sheep exhibited clinical signs characteristic of bluetongue virus disease. Circulating virus was demonstrated after 8 days post inoculation (DPI) and remained detectable for the remainder of the time course (24 DPI). A distinct lymphopenia was observed between 7 and 14 DPI that rebounded to mock-inoculated control levels at 17 DPI. In addition, we observed increased expression of pro-inflammatory cytokines after 8 DPI. Taken together, we have established a model of BTV infection in sheep and have successfully monitored the longitudinal vertebrate host immunological response and viral infection progression using a combination of traditional methods and cutting-edge technology.
Collapse
Affiliation(s)
- Joseph A Westrich
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA
| | - Erin E McNulty
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA
| | - Molly Carpenter
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA
| | - Mollie Burton
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA
| | - Kirsten Reed
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA
| | - Amy Nalls
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA
| | - Audrey Sandoval
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA
| | - Christie Mayo
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA
| | - Candace K Mathiason
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA.
| |
Collapse
|
2
|
Bamouh Z, Es-Sadeqy Y, Safini N, Douieb L, Omari Tadlaoui K, Martínez RV, García MA, Fassi-Fihri O, Elharrak M. Safety and efficacy of a Bluetongue inactivated vaccine (serotypes 1 and 4) in sheep. Vet Microbiol 2021; 261:109212. [PMID: 34450450 DOI: 10.1016/j.vetmic.2021.109212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 08/16/2021] [Indexed: 11/27/2022]
Abstract
A new inactivated vaccine against Bluetongue virus (BTV) serotypes 1 and 4, was developed from field isolates. Safety and efficacy of the vaccine were evaluated in sheep by serological monitoring and virus nucleic acid detection after experimental infection of vaccinated animals. Seroconversion was observed in vaccinated animals at day 14 post vaccination (pv) with neutralizing antibody titer of 1.9 and 1.8 for serotypes 1 and 4, respectively. The titer increase significantly after the booster reaching 2.7 and persist one year >1.5 for both serotypes. After challenge with virulent isolates, vireamia was recorded in control animals, as evident by q-PCR with threshold cycles (Ct) ranging from 24 to 31 and peaked at day 10 post challenge, while no vireamia was detected in vaccinated animals. Vaccinated sheep were fully protected against the disease and infection.
Collapse
Affiliation(s)
- Z Bamouh
- Research and Development, MCI Santé Animale, Lot. 157, Z. I., Sud-Ouest (ERAC) B.P: 278, Mohammedia 28810, Morocco; Institut Agronomique et Vétérinaire Hassan II, Rabat, Morocco.
| | - Y Es-Sadeqy
- Research and Development, MCI Santé Animale, Lot. 157, Z. I., Sud-Ouest (ERAC) B.P: 278, Mohammedia 28810, Morocco.
| | - N Safini
- Research and Development, MCI Santé Animale, Lot. 157, Z. I., Sud-Ouest (ERAC) B.P: 278, Mohammedia 28810, Morocco.
| | - L Douieb
- Research and Development, MCI Santé Animale, Lot. 157, Z. I., Sud-Ouest (ERAC) B.P: 278, Mohammedia 28810, Morocco.
| | - K Omari Tadlaoui
- Research and Development, MCI Santé Animale, Lot. 157, Z. I., Sud-Ouest (ERAC) B.P: 278, Mohammedia 28810, Morocco.
| | | | - M Agüero García
- Laboratorio Central de Veterinaria-Animal Health, Algete, Madrid, Spain.
| | - O Fassi-Fihri
- Institut Agronomique et Vétérinaire Hassan II, Rabat, Morocco.
| | - M Elharrak
- Research and Development, MCI Santé Animale, Lot. 157, Z. I., Sud-Ouest (ERAC) B.P: 278, Mohammedia 28810, Morocco.
| |
Collapse
|
3
|
The Interplay between Bluetongue Virus Infections and Adaptive Immunity. Viruses 2021; 13:v13081511. [PMID: 34452376 PMCID: PMC8402766 DOI: 10.3390/v13081511] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2021] [Revised: 07/19/2021] [Accepted: 07/28/2021] [Indexed: 12/18/2022] Open
Abstract
Viral infections have long provided a platform to understand the workings of immunity. For instance, great strides towards defining basic immunology concepts, such as MHC restriction of antigen presentation or T-cell memory development and maintenance, have been achieved thanks to the study of lymphocytic choriomeningitis virus (LCMV) infections. These studies have also shaped our understanding of antiviral immunity, and in particular T-cell responses. In the present review, we discuss how bluetongue virus (BTV), an economically important arbovirus from the Reoviridae family that affects ruminants, affects adaptive immunity in the natural hosts. During the initial stages of infection, BTV triggers leucopenia in the hosts. The host then mounts an adaptive immune response that controls the disease. In this work, we discuss how BTV triggers CD8+ T-cell expansion and neutralizing antibody responses, yet in some individuals viremia remains detectable after these adaptive immune mechanisms are active. We present some unpublished data showing that BTV infection also affects other T cell populations such as CD4+ T-cells or γδ T-cells, as well as B-cell numbers in the periphery. This review also discusses how BTV evades these adaptive immune mechanisms so that it can be transmitted back to the arthropod host. Understanding the interaction of BTV with immunity could ultimately define the correlates of protection with immune mechanisms that would improve our knowledge of ruminant immunology.
Collapse
|
4
|
Es-Sadeqy Y, Bamouh Z, Ennahli A, Safini N, El Mejdoub S, Omari Tadlaoui K, Gavrilov B, El Harrak M. Development of an inactivated combined vaccine for protection of cattle against lumpy skin disease and bluetongue viruses. Vet Microbiol 2021; 256:109046. [PMID: 33780805 DOI: 10.1016/j.vetmic.2021.109046] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2020] [Accepted: 03/19/2021] [Indexed: 01/14/2023]
Abstract
Lumpy Skin Disease (LSD) and Bluetongue (BT) are the main ruminants viral vector-borne diseases. LSD is endemic in Africa and has recently emerged in Europe and central Asia as a major threat to cattle industry. BT caused great economic damage in Europe during the last decade with a continuous spread to other countries. To control these diseases, vaccination is the only economically viable tool. For LSD, only live-attenuated vaccines (LAVs) are commercially available, whilst for BT both LAVs and inactivated vaccines are available with a limited number of serotypes. In this study, we developed an inactivated, oil adjuvanted bivalent vaccine against both diseases based on LSDV Neethling strain and BTV4. The vaccine was tested for safety and immunogenicity on cattle during a one-year period. Post-vaccination monitoring was carried out by VNT and ELISA. The vaccine was completely safe and elicited high neutralizing antibodies starting from the first week following the second injection up to one year. Furthermore, a significant correlation (R = 0.9040) was observed when comparing VNT and competitive ELISA in BTV4 serological response. Following BTV4 challenge, none of vaccinated and unvaccinated cattle were registered clinical signs, however vaccinated cattle showed full protection from viraemia. In summary, this study highlights the effectiveness of this combined vaccine as a promising solution for both LSD and BT control. It also puts an emphasis on the need for the development of other multivalent inactivated vaccines, which could be greatly beneficial for improving vaccination coverage in endemic countries and prophylaxis of vector-borne diseases.
Collapse
Affiliation(s)
- Youness Es-Sadeqy
- Research and Development, MCI Santé Animale, ZI Sud-Ouest B.P: 278, Mohammedia, 28810, Morocco.
| | - Zahra Bamouh
- Research and Development, MCI Santé Animale, ZI Sud-Ouest B.P: 278, Mohammedia, 28810, Morocco
| | - Abderrahim Ennahli
- Research and Development, MCI Santé Animale, ZI Sud-Ouest B.P: 278, Mohammedia, 28810, Morocco
| | - Najete Safini
- Research and Development, MCI Santé Animale, ZI Sud-Ouest B.P: 278, Mohammedia, 28810, Morocco
| | - Soufiane El Mejdoub
- Research and Development, MCI Santé Animale, ZI Sud-Ouest B.P: 278, Mohammedia, 28810, Morocco
| | - Khalid Omari Tadlaoui
- Research and Development, MCI Santé Animale, ZI Sud-Ouest B.P: 278, Mohammedia, 28810, Morocco
| | - Boris Gavrilov
- Biologics Development, Huvepharma, 3A Nikolay Haytov Street, Sofia, 1113, Bulgaria
| | - Mehdi El Harrak
- Research and Development, MCI Santé Animale, ZI Sud-Ouest B.P: 278, Mohammedia, 28810, Morocco
| |
Collapse
|